Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Neoadjuvant Chemotherapy Does Not Give Survival Benefit Over Chemoradiation in Cervical Cancer

December 3rd 2023

Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.

The Role of dMMR in the Progression of Endometrial Cancer

November 29th 2023

David M. O’Malley, MD, details the definition of dMMR (mismatch repair deficiency), its prevalence in advanced endometrial cancer, and current treatment approaches for dMMR patients, with a focus on the potential for cure in recurrent/metastatic dMMR patients based on clinical trial data.

Shared Decision-Making in Advanced or Recurrent Endometrial Cancer

November 29th 2023

The panel discusses factors to consider when determining best treatment options for patients with recurrent or advanced endometrial cancer, including traditional clinical trial endpoints, cost, chance for cure versus disease control, and most importantly, patient preference.

Camrelizumab Plus Famitinib Shows Promise in Recurrent or Metastatic Cervical Cancer

November 29th 2023

The combination comprised of camrelizumab and famitinib showcased improved efficacy with a manageable safety profile vs camrelizumab monotherapy or investigator’s choice of chemotherapy in patients with recurrent or metastatic cervical cancer.

Nimotuzumab With Concurrent Chemoradiotherapy Shows Activity in Cervical Squamous Cell Carcinoma

November 28th 2023

Nimotuzumab given concurrently with chemoradiotherapy demonstrated efficacy and favorable tolerability in patients with locally advanced cervical squamous cell carcinoma, according to data from a randomized, controlled, open-label, multicenter study.

Retifanlimab Continues to Elicit Responses in Recurrent MSI-H or dMMR Endometrial Cancer

November 28th 2023

Retifanlimab-dlwr continued to elicit responses with acceptable tolerability in patients with recurrent microsatellite instability–high or mismatch–repair deficient endometrial cancer, according to final findings from cohort H of the phase 1 POD1UM-101 trial.

Cadonilimab Plus Chemo With or Without Bevacizumab Improves PFS in Recurrent or Metastatic Cervical Cancer

November 28th 2023

The frontline combination of cadonilimab and platinum-based chemotherapy with or without bevacizumab provided a progression-free survival benefit in patients with recurrent or metastatic cervical cancer.

Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status

November 27th 2023

Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.

Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab

November 27th 2023

Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.

Key Takeaways From the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting

November 27th 2023

Drs Backes and Powell highlight key advances in endometrial cancer treatment from the 2023 SGO, ASCO, and ESMO conferences, including HER2-targeted therapies showing promising response rates.

Recent Advances in Endometrial Cancer

November 27th 2023

Matthew Powell, MD, and Floor Backes, MD, discuss recent advances in the molecular profiling and staging of endometrial cancer.

Multidisciplinary Approaches in the Treatment of Low-Grade Serous Ovarian Cancer

November 22nd 2023

Dr O’Malley discusses strategies in collaborating with multidisciplinary teams for quality of life, fertility preservation, and management of treatment related side effects to optimize patient wellbeing.

Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

November 22nd 2023

Key opinion leaders review recent updates to the NCCN guidelines for treating recurrent and advanced endometrial cancer, including biomarker testing and targeted therapies like dostarlimab and trastuzumab.

Diagnosing and Staging Patients With Endometrial Cancer

November 22nd 2023

Expert gynecologic oncologists discuss recent progress in treating advanced endometrial and cervical cancers, including epidemiology, risk factors, evaluation, staging, and molecular testing.

Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab

November 20th 2023

Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.

HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment

November 20th 2023

The role of HER2 status and targeted therapy with trastuzumab in advanced endometrial cancer, emphasizing the need for effective management of cardiac toxicities and comorbidities.

Institutional Perspectives in Cancer- Gynecologic Cancers: Chaired by Michael Stany, MD

November 15th 2023

Institutional Perspectives in Cancer- Gynecologic Cancers: Chaired by Michael Stany, MD

Treatment Choices for Recurrent dMMR Endometrial Cancer

November 13th 2023

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.

Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy

November 13th 2023

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, discuss the prevalence of patients with recurrent endometrial cancer, challenges in responding to chemotherapy, and the potential for improved treatment options in the second-line setting.

State of the Science Summit - Gynecologic Cancers: Chaired by Matthew Powell, MD

November 12th 2023

State of the Science Summit - Gynecologic Cancers: Chaired by Matthew Powell, MD

NEXT PAGE
PREVIOUS PAGE